Reata Pharmaceuticals Inc (RETA):企業の財務・戦略的SWOT分析

◆英語タイトル:Reata Pharmaceuticals Inc (RETA) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C14810
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥44,400見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Reata Pharmaceuticals Inc (Reata) is a clinical-stage biopharmaceutical company that develops innovative medicines for the treatment of serious and life-threatening diseases. The company’s clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription factor, for restoring mitochondrial function, reducing oxidative stress, and resolving inflammation. Reata is evaluating bardoxolone methyl in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), Alport syndrome and other kidney diseases; and omaveloxolone in Friedreich’s ataxia. The company works in partnership with academics, biotechnology and pharmaceutical companies to develop technologies, which disrupt the pathophysiological processes that lead to intractable diseases. Reata is headquartered in Irving, Texas, the US.

Reata Pharmaceuticals Inc Key Recent Developments

Feb 28,2019: Reata Pharmaceuticals announces fourth quarter and full year 2018 financials and operating results
Feb 19,2019: NephCure Kidney International Launches Revolutionary Clinical Trial Discovery Tool For Kidney Diseases
Jan 07,2019: Reata Pharmaceuticals names Geoffrey A. Block, M.D. as Vice President, Nephrology
Nov 07,2018: Reata Pharmaceuticals announces third quarter 2018 financial results and an update on development programs
Aug 08,2018: Reata Pharmaceuticals announces second quarter 2018 financial results and an update on development programs

This comprehensive SWOT profile of Reata Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Reata Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Reata Pharmaceuticals Inc – Key Information
Reata Pharmaceuticals Inc – Overview
Reata Pharmaceuticals Inc – Key Employees
Reata Pharmaceuticals Inc – Key Employee Biographies
Reata Pharmaceuticals Inc – Key Operational Heads
Reata Pharmaceuticals Inc – Major Products and Services
Reata Pharmaceuticals Inc – History
Reata Pharmaceuticals Inc – Company Statement
Reata Pharmaceuticals Inc – Locations And Subsidiaries
Reata Pharmaceuticals Inc – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Reata Pharmaceuticals Inc – Business Description
Reata Pharmaceuticals Inc – Corporate Strategy
Reata Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Reata Pharmaceuticals Inc – Strengths
Reata Pharmaceuticals Inc – Weaknesses
Reata Pharmaceuticals Inc – Opportunities
Reata Pharmaceuticals Inc – Threats
Reata Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Reata Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Reata Pharmaceuticals Inc, Key Information
Reata Pharmaceuticals Inc, Key Ratios
Reata Pharmaceuticals Inc, Share Data
Reata Pharmaceuticals Inc, Major Products and Services
Reata Pharmaceuticals Inc, History
Reata Pharmaceuticals Inc, Key Employees
Reata Pharmaceuticals Inc, Key Employee Biographies
Reata Pharmaceuticals Inc, Key Operational Heads
Reata Pharmaceuticals Inc, Other Locations
Reata Pharmaceuticals Inc, Subsidiaries
Reata Pharmaceuticals Inc, Key Manufacturing facilities
Reata Pharmaceuticals Inc, Key Competitors
Reata Pharmaceuticals Inc, SWOT Analysis
Reata Pharmaceuticals Inc, Ratios based on current share price
Reata Pharmaceuticals Inc, Annual Ratios
Reata Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Reata Pharmaceuticals Inc, Performance Chart
Reata Pharmaceuticals Inc, Ratio Charts

★海外企業調査レポート[Reata Pharmaceuticals Inc (RETA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fidelity National Financial, Inc.:企業のM&A・事業提携・投資動向
    Fidelity National Financial, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fidelity National Financial, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Zhuhai Zhongfu Enterprise Company Limited:企業の戦略・SWOT・財務情報
    Zhuhai Zhongfu Enterprise Company Limited - Strategy, SWOT and Corporate Finance Report Summary Zhuhai Zhongfu Enterprise Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • ComfortDelGro Corporation Limited:企業の戦略・SWOT・財務情報
    ComfortDelGro Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary ComfortDelGro Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • A.H.A International Co., Ltd.:戦略・SWOT・企業財務分析
    A.H.A International Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary A.H.A International Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Revance Therapeutics Inc (RVNC)-医療機器分野:企業M&A・提携分析
    Summary Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The company’s product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of glabellar lines, cervical dystonia, and plantar fas …
  • Lundin Gold Inc:企業の戦略・SWOT・財務情報
    Lundin Gold Inc - Strategy, SWOT and Corporate Finance Report Summary Lundin Gold Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • CryoLife Inc (CRY):医療機器:M&Aディール及び事業提携情報
    Summary CryoLife Inc (CryoLife) is a provider of biosurgical devices and implantable living tissues for cardiac and vascular surgical procedures. The company’s portfolio enlists preserved human cardiac allografts, vascular allografts, surgical adhesives and sealants, heart valves, carbon dioxide dif …
  • China North Industries Corporation:企業の戦略・SWOT・財務情報
    China North Industries Corporation - Strategy, SWOT and Corporate Finance Report Summary China North Industries Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Eastman Kodak Company:企業の戦略・SWOT・財務情報
    Eastman Kodak Company - Strategy, SWOT and Corporate Finance Report Summary Eastman Kodak Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Refocus Group Inc:製品パイプライン分析
    Summary Refocus Group Inc (Refocus Group) is a medical equipment company that concentrates on research and development of treatments for human vision disorders. The company has developed visability implant system (VIS) for the treatment of presbyopia. Its VIS procedure is an outpatient procedure tha …
  • Hays plc (HAS):企業の財務・戦略的SWOT分析
    Hays plc (HAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • VION N.V.:企業の戦略・SWOT・財務情報
    VION N.V. - Strategy, SWOT and Corporate Finance Report Summary VION N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Svenska Handelsbanken AB:企業の戦略・SWOT・財務情報
    Svenska Handelsbanken AB - Strategy, SWOT and Corporate Finance Report Summary Svenska Handelsbanken AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Expro Holdings UK 2 Limited:企業の戦略的SWOT分析
    Expro Holdings UK 2 Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • ADMA Biologics Inc (ADMA):製薬・医療:M&Aディール及び事業提携情報
    Summary ADMA Biologics Inc (ADMA Biologics) is an integrated biopharmaceutical and specialty immunoglobulin company that develops, produces, and commercializes specialty biologics to treat immune deficiencies and prevent certain infectious diseases. The company develops RI-002, is a specialty plasma …
  • Amdocs Ltd (DOX):企業の財務・戦略的SWOT分析
    Amdocs Ltd (DOX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Emera Inc (EMA):電力:M&Aディール及び事業提携情報
    Summary Emera Inc (Emera) is an energy and services company. It invests in electricity, natural gas and utility energy services. Through ownership and equity investments in various companies, Emera generates, transmits and distributes electricity; procures, transmits and distributes natural gas; mar …
  • BioGaia AB (BIOG B):企業の財務・戦略的SWOT分析
    BioGaia AB (BIOG B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Molecular Warehouse Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Molecular Warehouse Ltd (Molecular Warehouse) is a developer of proteins for diagnostic and therapeutic use. The company helps prevent diseases by empowering people with molecular diagnostics. Its synthetic biology techniques enabled it to reengineer glucose dehydrogenase, and enzymes found …
  • Senzime AB (SEZI)-医療機器分野:企業M&A・提携分析
    Summary Senzime AB (Senzime) is a medical device company that develops patient-oriented monitoring systems. The company's product include TetraGraph monitor, CliniSenz analyzer, and Onzurf probe. Its TetraGraph monitor stimulates, measures, analyzes and displays muscle function in surgical patients …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆